Compare VRTX & SBUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | SBUX |
|---|---|---|
| Founded | 1989 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Restaurants |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 95.8B |
| IPO Year | 1991 | 1992 |
| Metric | VRTX | SBUX |
|---|---|---|
| Price | $459.29 | $89.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 23 |
| Target Price | ★ $501.42 | $98.61 |
| AVG Volume (30 Days) | 1.3M | ★ 8.4M |
| Earning Date | 02-09-2026 | 01-27-2026 |
| Dividend Yield | N/A | ★ 2.79% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 14.22 | 1.63 |
| Revenue | $11,723,300,000.00 | ★ $37,184,400,000.00 |
| Revenue This Year | $11.01 | $4.84 |
| Revenue Next Year | $8.74 | $7.04 |
| P/E Ratio | ★ $32.61 | $54.53 |
| Revenue Growth | ★ 10.33 | 2.79 |
| 52 Week Low | $362.50 | $75.50 |
| 52 Week High | $519.68 | $117.46 |
| Indicator | VRTX | SBUX |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 60.30 |
| Support Level | $443.12 | $85.66 |
| Resistance Level | $487.52 | $90.64 |
| Average True Range (ATR) | 9.35 | 2.31 |
| MACD | -0.29 | 0.42 |
| Stochastic Oscillator | 36.42 | 89.90 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Starbucks stands out as the world's biggest and most recognizable coffee brand, powered by ultracustomizable beverages in-store and a sweeping footprint of nearly 41,000 cafes in over 80 countries. About 52% are company-operated, with the balance run by licensees. The company operates roasteries and sells across its North America (74% of revenue as of the end of fiscal 2025), international (21%), and channel development (5%) segments. The brand collects revenue from company-operated stores, licensee royalties, equipment and product sales, retail ready-to-drink beverages, and packaged coffee.